Every Form 4 that Medline (MDLN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow MDLN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MDLN filings page.
Medline Inc. (MDLN) 10% owners GIC Private Ltd, GIC Special Investments Pte Ltd and Hux Investment Pte. Ltd. reported sales totaling 20,678,630 shares of Class A common stock across five transactions on October 2, 5 and 6, 2026. Reported prices included $35.35 and $34.33 per share on October 2, $35.78 on October 5, and $35.05 on October 6. The $35.35 and $35.78 prices were weighted averages, for transactions at $35.30–$35.70 and $35.59–$36.23, respectively.
The two indirect sales involved shares owned directly by Hux Investment, with GIC Private Ltd and GIC Special Investments sharing voting and disposition power. Each reporting person disclaimed beneficial ownership except to the extent of its pecuniary interest. No Rule 10b5-1 plan is reported.
Medline Inc. (MDLN) reported that Chief Executive Officer and director James M. Boyle received a grant/award of performance-based Incentive Units of Medline Holdings, LP on August 19, 2026. He acquired 764,252 fully vested Incentive Units, held indirectly through Medline Management Aggregator LLC, which are convertible into Common Units and then exchangeable one-for-one into Class A Common Stock with no expiration date.
Medline Inc. (symbol: MDLN) is the issuer of record for a Form 4 filing submitted to the SEC.
Entities associated with GIC reported sales of Medline Inc. (MDLN) stock. Hux Investment Pte. Ltd., together with GIC Special Investments Pte. Ltd. and GIC, reported open-market sales totaling 1,600,000 shares of Class A Common Stock at $35.80 per share on August 13–14, 2026. An indirect position of 91,555,447 shares is reported as held through Hux, with each reporting person and the Government of Singapore disclaiming beneficial ownership except to the extent of any pecuniary interest.
Medline Inc. large shareholders associated with GIC reported a sale of 590,284 shares of Class A Common Stock on 2026-08-07. The shares were sold at a weighted average price of $35.58 per share, with individual trade prices ranging from $35.20 to $35.72. After this transaction, the reporting persons show 24,402,482 shares held directly and a separate indirect holding of 91,555,447 shares through Hux Investment Pte. Ltd., subject to footnote disclosures that each reporting person disclaims beneficial ownership beyond its pecuniary interest.
Mozart Holdco, Inc., a 10% owner of Medline Inc. (MDLN), exchanged 500,000 Common Units of Medline Holdings, LP and cancelled 500,000 shares of non-economic Class B common stock for 500,000 shares of Class A common stock on August 6, 2026 under an Exchange Agreement. Following these conversions, it directly holds 787,648 Class A shares, 233,520,656 Common Units and 233,520,656 Class B shares, with Class B shares providing one vote per share and no economic value.
Medline Inc. major holders affiliated with GIC Private Ltd, GIC Special Investments Pte Ltd and Hux Investment Pte. Ltd. reported selling 2,248,612 shares of Class A Common Stock on August 5–6, 2026 in open-market or private transactions at weighted-average prices around the mid-$30s. A separate entry reports 91,555,447 shares of Class A Common Stock indirectly owned through Hux Investment Pte. Ltd., with Hux sharing voting and dispositive power with GIC Special Investments and GIC. Each reporting person, and the Government of Singapore, disclaims beneficial ownership except to the extent of its pecuniary interest. The Rule 10b5‑1 plan checkbox is not marked.
Medline Inc. executive William J. Abrams reported a routine tax-related share disposition. On June 15, 2026, 1,308 shares of Class A Common Stock were withheld at $36.61 per share to cover his tax liability from vesting restricted stock units. This was not an open-market sale, and Abrams continues to hold 16,546 shares directly after the transaction.
Medline Inc. Chief Human Resources Officer Christopher P. Shryock reported a routine tax-withholding transaction involving company stock. On the vesting of restricted stock units, 872 shares of Class A Common Stock were withheld at a value of $36.61 per share to satisfy his tax liability, as noted in the footnote. After this non-market disposition for taxes, he directly holds 11,031 shares of Medline common stock.
Medline Inc.'s Chief Operating Officer Stephen L. Miller reported a routine tax-related share disposition. On the vesting of restricted stock units, 1,889 shares of Class A Common Stock were withheld at $36.61 per share to cover his tax liability. This was not an open-market sale. Following the withholding, Miller directly holds 23,899 shares, so he retains the vast majority of his equity position.
Medline Inc. Chief Legal Officer Alexander M. Liberman reported a routine tax-related share disposition. On the reported date, 872 shares of Class A Common Stock were withheld to cover his tax liability arising from the vesting of restricted stock units. After this withholding, he directly holds 11,031 shares of Medline Class A Common Stock. This event reflects a standard administrative step tied to equity compensation rather than an open-market sale.
Medline Inc. Chief Product Officer Amanda H. Laabs reported a routine tax-related share disposition. On the reported date, 1,889 shares of Class A Common Stock were withheld to cover her tax liability arising from the vesting of restricted stock units, at a value of $36.61 per share. After this withholding, she directly holds 23,899 shares of Medline common stock. This event reflects compensation-related tax settlement rather than an open-market stock sale.
Medline Inc. Chief Financial Officer Michael B. Drazin reported a tax-withholding disposition related to equity compensation. On the vesting of restricted stock units, 1,889 shares of Class A Common Stock were withheld at $36.61 per share to cover taxes, leaving him with 23,899 shares held directly.
Medline Inc. Chief Commercial Officer and 10% owner Douglas P. Golwas reported a mix of equity transactions involving Medline stock and partnership units. He exercised 100,000 Common Units of Medline Holdings, LP into 100,000 shares of Class A common stock, while an equivalent 100,000 shares of Class B common stock were automatically cancelled and returned to the issuer with no economic value exchanged.
Golwas then sold 38,034 Class A shares at a weighted average price of $37.05 per share and 61,966 Class A shares at a weighted average price of $36.60 per share, both under a pre-arranged Rule 10b5-1 trading plan. In a separate move tied to restricted stock unit vesting, 1,889 Class A shares were withheld to cover tax obligations. Following these transactions, he continues to hold significant direct Class A ownership and 365,864 Common Units of Medline Holdings, LP indirectly, each exchangeable one-for-one into Class A shares.
Medline Inc. director and Chief Executive Officer James M. Boyle reported a routine tax-related share disposition. The filing shows that 2,370 shares of Class A Common Stock were withheld at $36.61 per share to cover his tax liability linked to vesting restricted stock units. After this non-market transaction, Boyle directly holds 29,369 shares of Medline Inc. common stock.
GALANTI RICHARD A reported acquisition or exercise transactions in this Form 4 filing.
Medline Inc. director Richard A. Galanti reported stock-based compensation awards rather than open‑market purchases. He received 5,387 shares of Class A Common Stock as a grant at a price of $0.00 per share, bringing his direct holdings to 16,392 shares. Footnotes explain these are restricted stock units that vest either on March 30, 2027 or on the earlier of the first anniversary of grant and the next annual meeting of stockholders.
Sweet Thomas W reported acquisition or exercise transactions in this Form 4 filing.
Medline Inc. director Thomas W. Sweet reported equity awards rather than open‑market trades. On June 11, 2026, he received 5,387 shares of Class A Common Stock as a grant of restricted stock units at no cash cost, giving him 5,387 shares held directly after the grant.
The filing also reflects a prior award of 12,413 Class A shares on December 16, 2025, held indirectly through Mallard Advisory LLC, where he is a manager. Those restricted stock units vest on the earlier of the first anniversary of grant or the next annual stockholder meeting, illustrating standard director compensation in stock.
Medline Inc. director Todd M. Bluedorn reported stock-based compensation awards rather than open-market trades. He received 5,387 shares of Class A Common Stock on June 11, 2026 as a grant of restricted stock units (RSUs) that vest on the earlier of the first anniversary of grant or the next annual stockholder meeting. An earlier RSU grant of 10,345 shares on December 16, 2025 is also shown, vesting on March 30, 2027. Following the most recent award, he directly holds 15,732 shares of Medline Class A Common Stock, all acquired through grants.
Medline Inc. Principal Accounting Officer Jessi L. Corcoran reported an open-market purchase of Class A Common Stock. On June 5, 2026, Corcoran bought 5,000 shares at a price of $34.15 per share, bringing her directly held stake to 5,000 shares.
Medline Inc. large shareholders affiliated with Hellman & Friedman reported significant open-market sales of Class A Common Stock alongside internal reallocations. On May 28, 2026, affiliated funds sold a combined 31,868,237 shares at an effective price of $36.5375 per share, reflecting the $37.00 secondary public offering price less a $0.4625 underwriting discount. The transactions were executed through an underwritten public offering, with sales attributed to entities including Hellman & Friedman Capital Partners X (Parallel), L.P., HFCP X (Parallel - A), L.P., Mend Partners II, L.P., and Mend Investment Holdings I, L.P. The filing also notes in-kind distributions of shares from certain funds to their ultimate partners and shareholders, and that distributed shares (other than a small charitable portion) are subject to a lock-up agreement with the underwriters.
Medline Inc. director Patrick J. Healy reported trust-related movements in Class A common stock, rather than open-market trading. A distribution in kind shifted shares previously held by investment funds into entities associated with the reporting person and a family trust.
After these J-code “other” transactions on the same date, 179,762 shares were held directly, 172,383 shares were held indirectly through a family trust, and 39,189 shares were held indirectly through a children’s trust. The filing notes that Healy disclaims beneficial ownership of trust-held shares beyond his pecuniary interest.
Medline Inc. reported that investment vehicles affiliated with Blackstone reduced part of their indirect stake in the company. On May 28, 2026, these entities sold an aggregate of 33,317,824 shares of Class A common stock in connection with a secondary offering at about $36.5375 per share, the public price net of underwriting discounts. The filing also shows a J-code in-kind distribution of 438,214 shares from Mozart Aggregator II LP to one of its investors and related entities, which remain subject to lock-up restrictions. Despite these sales and distributions, affiliated entities continue to hold large indirect positions, including 89,537,913 shares of Class A common stock after the reported transactions.
Medline Inc. reported a large shareholder sale of Class A common stock by investment entities that are ten percent owners. On May 28, 2026, the reporting entities executed open‑market or private sales totaling 33,317,824 shares of Class A common stock at a price of $36.5375 per share. A footnote explains these sales were made to underwriters in connection with the closing of a secondary offering at a public offering price of $37.00 per share, less underwriting discounts and commissions of $0.4625 per share.
The filing also reports an "other" transaction involving an in‑kind distribution of 438,214 shares of Class A common stock by Mozart Aggregator II LP to one of its investors and certain affiliated entities. Those distributees agreed in writing to be bound by the restrictions in an existing lock‑up agreement with the underwriters. The reporting persons state they disclaim beneficial ownership of securities held by other reporting persons except to the extent of their pecuniary interest.
Medline Inc. insiders reported a restructuring of their indirect holdings through conversions of partnership units into Class A common stock, with no open-market buying or selling. Blackstone-affiliated entities exchanged 1,489,924 and 9,858,774 Common Units of Medline Holdings, LP for the same number of Medline Class A shares at a stated price of $0.00 per share under an exchange agreement allowing one-for-one conversions that do not expire.
Each converted Common Unit had a corresponding share of Class B common stock, which carried voting rights but no economic value and was automatically cancelled on conversion. After these conversions, the entities report indirect ownership of Class A shares and remaining Common Units, while broadly disclaiming beneficial ownership of securities held by related reporting persons except to the extent of their pecuniary interest.
Medline Inc. and Blackstone-affiliated entities reported internal equity moves involving Medline Holdings, LP units and Medline Class A and Class B stock. On May 21, 2026, entities converted a total of 11,348,698 Common Units of Medline Holdings, LP into an equal number of Medline Class A common shares at a stated price of $0.0000 per unit.
The same number of Medline Class B common shares, which have one vote per share but no economic value, were automatically cancelled in connection with these exchanges. After the transactions, indirect Class A holdings for the reporting group remain large, including 109,250,239 Class A shares reported as held indirectly by one Blackstone-related entity.
Medline Inc. entities reported a large internal equity conversion involving 18,156,867 units. Mend Investment Holdings I, L.P. exchanged 18,156,867 Common Units of Medline Holdings, LP for an equal number of Medline Inc. Class A Common Stock at a stated price of $0.0000 per share.
In connection with this exchange, an equivalent 18,156,867 shares of Class B Common Stock held by Mend Investment Holdings I, L.P. were automatically cancelled. Class B shares carry one vote per share but have no economic value and are paired one-for-one with Common Units.
After these transactions, Mend Investment Holdings I, L.P. is shown holding 18,176,177 shares of Class A Common Stock and 82,453,349 Common Units indirectly, while related Hellman & Friedman funds report additional indirect Class A holdings through other entities. The filing reflects a restructuring and conversion of interests rather than open‑market buying or selling.
Medline Inc. director Patrick J. Healy reported internal restructuring transactions involving Class A common stock, not open-market buying or selling. The filing shows a distribution in kind from investment funds affiliated with Hellman & Friedman to Healy and a related family trust.
After these transactions, Healy holds 1,208,159 Class A shares directly and 150,039 shares indirectly through a family trust, with an additional 39,189 shares held indirectly through a children's trust. The trusts are for the benefit of certain family members, and Healy disclaims beneficial ownership of those trust-held shares except to the extent of his pecuniary interest.
Medline Inc. major shareholder group led by The Carlyle Group Inc. reported a large secondary sale of Class A common stock. On 2026-03-10, entities affiliated with Carlyle sold 26,105,840 shares of Class A Common Stock at $41.00 per share in open-market or private transactions.
In a separate move the same day, Carlyle Mozart Coinvestment Holdings, L.P. made a pro-rata distribution of 2,113,483 Class A shares to its limited partner for no consideration, with those distributed shares subject to lock-up restrictions. After these transactions, Carlyle-affiliated entities reported indirect ownership of 125,454,241 Class A shares across multiple investment vehicles.
Carlyle-affiliated investment funds reduced their indirect stake in Medline Inc. through a large open-market sale and a separate non-cash distribution. The funds sold 26,105,840 shares of Class A common stock at $41 per share in open-market or private transactions.
Separately, 2,113,483 shares were distributed pro rata for no consideration by Carlyle Mozart Coinvestment Holdings, L.P. to one of its limited partners under a lock-up agreement that restricts the distributed shares. After these transactions, the Carlyle-related entities together report indirect ownership of 125,454,241 Medline Class A shares.
Medline Inc. insiders reported a large secondary sale of Class A Common Stock by Carlyle-affiliated funds. Entities associated with The Carlyle Group sold 26,105,840 shares of Medline Class A Common Stock at $41.00 per share in an open-market or private transaction, reducing but not eliminating their indirect stake.
Separately, 2,113,483 shares were moved in an "other" transaction described as a pro-rata distribution for no consideration by Carlyle Mozart Coinvestment Holdings, L.P. to its limited partner, which remains subject to lock-up restrictions. After these transactions, the reporting entities collectively hold 125,454,241 Medline Class A shares indirectly.
Medline Inc. reported a large insider transaction by investment entities affiliated with The Carlyle Group Inc. On March 10, 2026, these entities sold 26,105,840 shares of Medline Class A Common Stock in an open-market or private transaction at $41.00 per share, through various affiliated limited partnerships.
The filing also shows a separate J-code transaction for 2,113,483 shares, described as a pro-rata distribution for no consideration from Carlyle Mozart Coinvestment Holdings, L.P. to its limited partner, which remains subject to lock-up restrictions. After these transactions, the reporting group continues to indirectly hold about 125,454,241 shares of Medline Class A Common Stock.
Medline Inc. (MDLN) major shareholders tied to Blackstone reported large secondary sales of Class A common stock. On March 10, 2026, entities associated with these reporting persons sold a combined 27,852,986 shares of Class A common stock in open-market or related transactions at $40.508 per share, in connection with the closing of a secondary offering where shares were sold to underwriters at the public offering price of $41.00 per share less underwriting discounts and commissions of $0.492 per share.
The filing also reports an "other" transaction involving an in-kind distribution of 366,337 shares of Class A common stock by Mozart Aggregator II LP to one of its investors and certain affiliated entities, which agreed in writing to remain subject to the existing lock-up agreement. Following these transactions, the Blackstone-related holding structures continue to own substantial indirect positions, including 109,250,239 shares and 12,507,704 shares of Class A common stock held through specific Mozart aggregator entities as reflected in the filing.
Medline Inc. large shareholders affiliated with the Mozart and Blackstone investment vehicles reported significant sales of Class A Common Stock. On March 10, 2026 they executed four open-market or private sale transactions totaling 27,852,986 shares at $40.508 per share, in connection with a secondary offering where shares were sold to underwriters at the public offering price of $41.00 per share less underwriting discounts and commissions of $0.492 per share.
The filing also reports an additional J‑code transaction for 366,337 shares at a stated price of $0.00 per share, representing in‑kind distributions of Class A Common Stock from Mozart Aggregator II LP to one of its investors and affiliated entities, which remain subject to lock‑up restrictions. All positions are held indirectly through various partnership and limited liability company structures, and each reporting person disclaims beneficial ownership of securities held by the others except to the extent of its pecuniary interest.
Medline Inc. significant shareholders affiliated with Hellman & Friedman reported large secondary sales of Class A Common Stock. Investment vehicles including Hellman & Friedman Capital Partners X (Parallel), L.P., HFCP X (Parallel-A), L.P., Mend Investment Holdings I, L.P., and Mend Partners II, L.P. sold an aggregate of 26,131,237 shares on March 10, 2026 at an effective price of $40.508 per share, reflecting the $41.00 secondary public offering price less a $0.492 underwriting discount in an underwritten public offering.
Additional non-cash “J” code entries show internal contributions of shares to wholly owned subsidiaries and in-kind distributions of Class A Common Stock to ultimate partners and shareholders in connection with these sales. Following the transactions, the funds still report substantial indirect holdings, including 75,931,567 shares for Hellman & Friedman Capital Partners X (Parallel), L.P. and 7,895,482 shares for HFCP X (Parallel-A), L.P. Recipients of distributed shares have generally agreed to lock-up restrictions, with an exception for less than 1% of outstanding stock delivered to charitable organizations.
Medline Inc. reported that investment entities affiliated with The Carlyle Group Inc. exchanged Common Units of Medline Holdings, LP for shares of Medline Class A common stock on March 4, 2026 and March 5, 2026. Each Common Unit converted into one Class A share at a stated price of $0.0000 per share.
On March 4, 2026, 8,085,116 Common Units were converted into 8,085,116 Class A shares, and on March 5, 2026, 1,212,767 Common Units were converted into 1,212,767 Class A shares. An equivalent number of Class B common shares, which have no economic value and one vote per share, were cancelled in connection with these exchanges.
TC Group Cayman Investment Holdings, L.P. reported acquisition or exercise transactions in this Form 4 filing.
Medline Inc. large shareholders affiliated with TC Group and Carlyle reported internal equity restructurings. On March 4 and 5, 2026, entities exchanged a total of 8,085,116 and 1,212,767 Common Units of Medline Holdings, LP for the same number of Medline Class A common shares at a stated price of $0.00 per share.
Following these exchanges, indirect holdings rose to 152,460,797 and then 153,673,564 shares of Class A common stock across the listed investment vehicles. Matching numbers of Class B common shares, which carry voting rights but no economic value, were automatically cancelled as the related Common Units were exchanged.
Medline Inc. insiders reported large equity structure moves tied to exchange rights in Medline Holdings, LP. On March 4 and 5, 2026, entities including CP Circle ML and CP Circle UNLV funds converted a total of 9,298,883 Common Units of Medline Holdings, LP into the same number of Class A Common Stock at a stated price of $0.00 per share under a one-for-one exchange agreement. An equivalent number of Class B Common Stock shares, which have voting rights but no economic value, were automatically cancelled as those units were exchanged, shifting ownership from partnership units into publicly traded Class A shares while keeping economic exposure intact.
Carlyle-affiliated investment entities that are 10% owners of Medline Inc. reported non-cash conversions of partnership units into Medline equity. On March 4, 2026 they converted 8,085,116 Common Units of Medline Holdings, LP into the same number of shares of Medline Class A common stock at a stated price of $0.00 per share.
On March 5, 2026 they converted an additional 1,212,767 Common Units into an equal number of Class A shares, again at $0.00 per share. In connection with these exchanges, an equivalent number of Class B common shares, which have no economic value and one vote per share, were cancelled as the corresponding Common Units were exchanged.
Medline Inc. insider filing shows a large equity conversion by affiliated investment funds. Mend Investment Holdings I, L.P. exchanged 13,198,914 Common Units of Medline Holdings, LP for the same number of Medline Inc. Class A common shares on March 4, 2026, and 1,979,837 Common Units for an equal number of Class A shares on March 5, 2026, both at a stated price of $0.00 per share.
In each case, an equivalent number of Class B common shares held by Mend Investment Holdings I, L.P. were automatically cancelled, consistent with the structure where one Class B share is paired with each Common Unit and has voting but no economic rights. The transactions are reported as indirect holdings by various Hellman & Friedman–affiliated entities, with a three‑member board of Investors X Ltd. holding voting and investment discretion and its directors disclaiming beneficial ownership.
Medline Inc. large holders reported conversions of partnership units into Class A common stock. Under a December 16, 2025 exchange agreement, holders of Common Units of Medline Holdings, LP may exchange units one-for-one for Medline Class A common stock, with customary anti-dilution adjustments.
On March 4 and 5, 2026, affiliated investment entities managed by Blackstone converted sizeable blocks of Common Units into Class A shares at a stated price of $0.00 per share, including 7,166,716 Common Units on March 4 and 1,075,007 on March 5. Matching numbers of Class B common shares, which have voting rights but no economic value, were automatically cancelled upon each conversion.
The report shows these securities are held indirectly through multiple Mozart and Blackstone-sponsored holding partnerships and limited liability companies, with one line item indicating 125,729,322 shares of Class A common stock held indirectly as of March 4, 2026.
Medline Inc. reporting entities led by BX Mozart ML-1 Holdco L.P. and Mozart Aggregator UNLV Holdco L.P. reported indirect acquisitions of Class A common stock through conversions of Common Units of Medline Holdings, LP on March 4 and March 5, 2026. The transactions used exchange rights that allow Common Units to be swapped for Class A shares on a one-for-one basis, at a stated price of $0.0000 per share. Related entries show Class B common stock, which has one vote per share but no economic value, being automatically cancelled in the same amounts as the converted Common Units. The filing also notes complex ownership chains among Blackstone-related entities and states that each reporting person, other than to the extent it directly holds securities, disclaims beneficial ownership of securities held by the others.
Medline Inc. Chief Commercial Officer Douglas P. Golwas reported equity awards and related ownership interests tied to the company’s pre-IPO reclassification and ongoing incentive programs. He acquired 25,788 shares of Class A common stock through a restricted stock unit grant at a price of $0.00 per share, with 25% vesting on June 15, 2026 and the remaining 75% vesting in three equal annual installments beginning on March 1, 2027.
On December 16, 2025, entities associated with him also acquired 465,864 Common Units of Medline Holdings, LP and a matching 465,864 shares of Class B common stock at $0.00 per share, in connection with the partnership’s reclassification prior to Medline’s initial public offering. Additional awards included several tranches of Incentive Units of Medline Holdings, LP totaling 948,597, 463,211, 212,755, 157,800 and 149,005 units, which function as profit interests similar to stock appreciation rights and are convertible into Common Units on specified terms. These Common Units and Incentive Units are held indirectly through Medline Management Aggregator LLC and a trust for which Golwas serves as trustee, with various vesting schedules extending into 2026 and beyond.
Medline Inc. executive William J. Abrams reported equity awards and partnership interests, with all transactions reflecting acquisitions rather than open-market trades. On March 5, 2026, he received a grant of 17,854 shares of Class A common stock in the form of restricted stock units, vesting 25% on June 15, 2026 and the remaining 75% in three equal annual installments beginning on March 1, 2027.
Earlier, on December 16, 2025, he acquired various Common Units and Incentive Units of Medline Holdings, LP, some held indirectly through Medline Management Aggregator LLC and a trust where he serves as trustee. Those interests were issued in connection with a reclassification prior to Medline’s initial public offering and were previously reported on his Form 3. Class B common stock carries voting rights but no economic value and is paired one-for-one with Common Units, and related Class B shares are cancelled when Common Units are exchanged into Class A common stock.
Medline Inc. director and CEO James M. Boyle reported only equity acquisitions, with no sales. He received 31,739 shares of Class A common stock as a restricted stock unit grant, with 25% vesting on June 15, 2026 and the remaining 75% vesting in three equal annual installments beginning on March 1, 2027.
Boyle is also credited with acquiring large blocks of Common Units and Incentive Units of Medline Holdings, LP on December 16, 2025, many held indirectly through a family trust and Medline Management Aggregator LLC. Footnotes describe Incentive Units as profit interests convertible into Common Units, which are exchangeable one-for-one into Class A common stock under an exchange agreement, with various tranches already partially vested and others vesting in scheduled annual installments through dates including April 1, 2026, October 1, 2026, October 21, 2026, March 28, 2026 and March 29, 2026.
Medline Inc. Chief Operating Officer Stephen L. Miller reported equity awards in the form of restricted stock units and partnership incentive units. He acquired 25,788 restricted stock units of Class A common stock at a price of $0.00 per unit. According to the terms, 25% of these units vest on June 15, 2026, with the remaining 75% vesting in three equal annual installments beginning on March 1, 2027.
He also acquired multiple blocks of Incentive Units of Medline Holdings, LP, which are described as profit interests with economic characteristics similar to stock appreciation rights. These vested Incentive Units can be converted into common units of Medline Holdings, LP based on the public trading price of Medline Class A common stock and a per unit participation threshold, and those common units are exchangeable on a one‑for‑one basis for shares of Class A common stock under an exchange agreement dated December 16, 2025. The Incentive Units have no expiration date, are held indirectly through Medline Management Aggregator LLC and a trust for which Miller serves as trustee, and vest over several annual installments beginning in 2026.
Medline Inc. Chief Human Resources Officer Christopher P. Shryock reported equity compensation awards rather than open‑market trades. He received 11,903 shares of Class A common stock as a restricted stock unit grant, with 25% vesting on June 15, 2026 and the remaining 75% vesting in three equal annual installments beginning March 1, 2027.
He also acquired 496,049 and 40,638 Incentive Units of Medline Holdings, LP, held indirectly through Medline Management Aggregator LLC. These Incentive Units are profit interests with economics similar to stock appreciation rights, convertible into common units of Medline Holdings, LP and then exchangeable one‑for‑one into Class A common stock, subject to vesting schedules described in the footnotes.
Medline Inc. Chief Financial Officer Michael B. Drazin reported a series of equity awards and ownership changes. On March 5, 2026, he received a grant of 25,788 restricted stock units of Class A common stock at no cash cost, with 25% vesting on June 15, 2026 and the remaining 75% vesting in three equal annual installments beginning on March 1, 2027.
Earlier, on December 16, 2025, interests in Medline Holdings, LP were reclassified in connection with Medline’s initial public offering. In that reclassification and related awards, entities associated with Drazin acquired 486,028 Common Units of Medline Holdings, LP and corresponding 486,028 shares of Class B common stock, as well as multiple blocks of Incentive Units of Medline Holdings, LP held indirectly through Medline Management Aggregator LLC. Common Units are exchangeable one-for-one into Class A common stock under an exchange agreement, while Class B shares carry voting rights but no economic value and are cancelled when Common Units are exchanged.
Medline Inc. Chief Product Officer Amanda H. Laabs reported equity awards rather than open‑market trades. On March 5, 2026, she acquired 25,788 shares of Class A common stock at $0.00 per share as a grant of restricted stock units. According to the disclosure, 25% of these RSUs vest on June 15, 2026, with the remaining 75% vesting in three equal annual installments beginning on March 1, 2027.
The filing also details prior awards from December 16, 2025, including 251,070 Common Units of Medline Holdings, LP and several tranches of Incentive Units, all acquired at $0.00 per unit. These units are held indirectly through Medline Management Aggregator LLC and can be exchanged into Common Units, which in turn are exchangeable on a one‑for‑one basis for Class A common stock under an exchange agreement. Class B common stock, issued one share for each Common Unit, carries voting rights but no economic value and is cancelled upon exchange into Class A shares.
Medline Inc. Chief Legal Officer Alexander M. Liberman reported multiple equity awards that increase his direct and indirect ownership interests. On March 5, 2026, he received 11,903 shares of Class A common stock for no cash consideration, described as restricted stock units that vest over time.
Earlier awards dated December 16, 2025 include Class B common stock, Common Units of Medline Holdings, LP and Incentive Units of Medline Holdings, LP, many held indirectly through a trust where his spouse is trustee and through Medline Management Aggregator LLC. These Common Units are exchangeable one-for-one into Class A common stock under an exchange agreement, while Incentive Units are profit interests that can convert into Common Units when vested and in the money.
CP Circle Holdings, L.P., a former large Medline holder, reported internal transfers of its Medline-related interests to an affiliated entity. On February 11, 2026, it moved 2,615 shares of Class A common stock, 15,369,974 shares of Class B common stock, and 15,369,974 Common Units of Medline Holdings, LP for no consideration under a lock-up agreement.
The filing states that after these transfers CP Circle Holdings, L.P. no longer beneficially owns Medline securities. Class B shares carry one vote per share and no economic value, and are paired one-for-one with Common Units. Common Units are exchangeable into Class A shares on a one-for-one basis under an exchange agreement.